Related Experiment Video
Updated: Sep 11, 2025
06:53
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
Published on: June 8, 2019
8.8K
Genome-wide cfDNA fragmentation patterns in cerebrospinal fluid reflect medulloblastoma groups
Alexander L Markowitz1, Chetan Munugula1, Eirini Christodoulou1
1Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA.
NPJ Precision Oncology
|August 12, 2025
Summary
Analyzing cerebrospinal fluid cell-free DNA (cfDNA) fragmentation patterns offers a minimally-invasive method for medulloblastoma diagnosis. This approach accurately distinguishes molecular groups, paving the way for improved personalized treatment strategies.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Accurate medulloblastoma molecular subtyping is crucial for effective treatment.
- Current diagnostic methods, such as biopsies, are invasive and burdensome for patients.
Purpose of the Study:
- To evaluate the potential of cerebrospinal fluid cell-free DNA (cfDNA) fragmentomics as a minimally-invasive diagnostic tool for medulloblastoma.
- To determine if cfDNA fragmentation patterns can accurately differentiate between the four main molecular groups of medulloblastoma.
Main Methods:
- Analysis of cfDNA fragmentation patterns from 122 cerebrospinal fluid samples.
- Utilized established group-specific copy number alterations for validation.
- Developed and applied an integrated meta-classifier to distinguish molecular groups.
Main Results:
- Distinct cfDNA fragmentation patterns were identified for each medulloblastoma molecular group.
- The meta-classifier achieved high accuracy (mean-AUC 0.94) in distinguishing the four groups.
- Confirmed known group-specific copy number alterations through cfDNA analysis.
Conclusions:
- cfDNA fragmentomics represents a promising, minimally-invasive approach for medulloblastoma molecular subtyping.
- This technique has the potential to enhance diagnostic accuracy and guide personalized treatment strategies.
- Further research can validate cfDNA fragmentomics for routine clinical application in pediatric oncology.
